Financial Data and Key Metrics Changes - Total net revenue for Q3 2025 was $314 million, a 2% increase year-over-year, driven by a 15% increase in SUBLOCADE net revenue to $219 million [18][19] - Adjusted EBITDA for Q3 2025 was $120 million, up 14% compared to the same quarter last year, attributed to higher net revenue and lower operating expenses [20] - The company raised its full-year 2025 total net revenue guidance to a range of $1.18 billion to $1.22 billion, reflecting better-than-expected performance [20][21] Business Line Data and Key Metrics Changes - SUBLOCADE experienced a strong 15% year-over-year growth, with dispense volume growth of 8% compared to the prior year [3][19] - The number of active SUBLOCADE prescribers grew by 11% year-over-year, indicating improved commercial execution [12] - SUBOXONE Film pricing remained stable, contributing to the overall revenue despite expected pricing pressure [18][19] Market Data and Key Metrics Changes - In the U.S., total net revenue grew by 2% year-over-year, with adjusted EBITDA increasing by 14% [4] - The market share for SUBLOCADE in the long-acting injectable (LAI) category remained stable at approximately 75% [12] - The company is optimizing its rest of world business, focusing on Australia, Canada, France, and Germany, which together generate 77% of forecasted rest of world net revenue [8] Company Strategy and Development Direction - The company is focused on completing Phase One of the Indivior Action Agenda, "Generate Momentum," and plans to enter Phase Two, "Accelerate," on January 1, 2026 [5][9] - Key priorities include growing SUBLOCADE in the U.S. and simplifying the organization to enhance operational efficiency [6][7] - A new direct-to-consumer campaign, "Move Forward in Recovery," was launched to raise awareness of SUBLOCADE as a treatment option [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in finishing 2025 with momentum and entering Phase Two with a strong position [9][25] - The company anticipates significant profitability and cash generation acceleration in 2026 [9][24] - Management emphasized the importance of maximizing the SUBLOCADE opportunity in the U.S. while ensuring essential investments [31] Other Important Information - The company has taken actions to reduce operating expenses by at least $150 million annually starting in 2026, primarily through headcount reduction and discontinuation of non-essential activities [6][30][23] - Non-GAAP operating expenses for Q3 2025 were $145 million, down 3% year-over-year [20] Q&A Session Summary Question: Can you break down the new $150 million OpEx cuts for 2026? - Management indicated that almost half of the $150 million savings is tied to labor, with a headcount reduction of over 32% and discontinuation of non-essential spending [30] Question: How does SG&A as a percentage of revenue compare to industry peers? - Management stated that the focus is on maximizing SUBLOCADE opportunities rather than targeting specific SG&A reductions [31] Question: Can you discuss the opportunity in commercial patients versus Medicaid? - Management highlighted efforts to grow both commercial and Medicaid channels, with a focus on improving commercial execution [37] Question: What are the expectations for SUBLOCADE growth in 2026? - Management is optimistic about maintaining double-digit year-over-year growth for SUBLOCADE, with a focus on commercial execution and direct-to-consumer campaigns [46] Question: What is the outlook for R&D spending going forward? - Management confirmed that R&D spending will be streamlined, focusing on Phase Two assets while preserving capabilities for potential Phase Three advancements [39][56]

Q3 2025 Performance Highlights - Total net revenue increased by 2% to $314 million compared to $307 million in Q3 2024[11] - SUBLOCADE net revenue increased by 15% to $219 million compared to $191 million in Q3 2024[11] - Adjusted EBITDA increased by 14% to $120 million compared to $105 million in Q3 2024[11] Financial Guidance Update - Total net revenue guidance raised to $1180 million - $1220 million, a 1% increase compared to previous guidance[34] - SUBLOCADE net revenue guidance raised to $825 million - $845 million, a 10% increase compared to previous guidance[34] - Adjusted EBITDA guidance raised to $400 million - $420 million, a 15% increase compared to previous guidance[34] Strategic Initiatives - The company is executing Phase I of the Indivior Action Agenda, focusing on generating momentum[13, 42] - Expect at least $150 million in Non-GAAP operating expense savings in 2026[17, 35] - U S SUBLOCADE YTD net revenue growth of 7% to $561 million compared to $524 million[17]

Financial Data and Key Metrics Changes - Total net revenue for Q2 2025 was $300 million, an increase of 1% year-over-year, driven by record SUBLOCADE net revenue which offset pricing pressure on SUBOXONE Film [28][29] - Total SUBLOCADE net revenue reached $209 million, a 9% increase compared to Q2 2024 and a 19% increase sequentially [29] - Adjusted EBITDA for Q2 was $88 million, slightly down from the previous year due to increased marketing expenses [31] - The company raised its full-year 2025 net revenue guidance to a range of $1.03 billion to $1.08 billion, reflecting solid performance [33][34] Business Line Data and Key Metrics Changes - SUBLOCADE's dispense growth was 6% year-over-year and 9% sequentially, with market share in the U.S. remaining stable at approximately 75% [21] - The number of active SUBLOCADE prescribers increased by 14% year-over-year, indicating a solid base for future growth [22] - SUBOXONE Film outperformed expectations with a market share of 14% and benefited from stable pricing [29][30] Market Data and Key Metrics Changes - The company noted that the commercial channel represents a significant opportunity, with only 25% of SUBLOCADE volume coming from commercial patients despite 60% of covered lives being commercial [44][81] - Payer response to new dosing approaches for SUBLOCADE has been positive, with coverage reaching approximately 80% of covered lives [24] Company Strategy and Development Direction - The Indivior Action Agenda is a three-phased operational roadmap aimed at maximizing business potential and creating shareholder value, with Phase One focused on generating momentum for SUBLOCADE [10][12] - The company plans to simplify operations by eliminating non-essential activities and restructuring its R&D and medical affairs organizations [12][17] - Future phases aim to accelerate growth and profitability, with a focus on commercial stage acquisitions starting in 2026 [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed encouragement about the performance in the first half of 2025 but acknowledged the need for improvement in U.S. commercial execution [8][16] - The opioid crisis remains a significant focus, with management advocating for broader access to treatments for opioid use disorder [76][78] - The company is optimistic about the potential for SUBLOCADE, citing low long-acting injectable penetration rates as an opportunity for growth [42][78] Other Important Information - Indivior canceled its secondary listing on the London Stock Exchange to reduce costs and complexity [35] - The company was added to the U.S. Russell Indexes, enhancing its visibility among U.S. investors [35] Q&A Session Summary Question: Opportunity in commercially covered patients vs. Medicaid - Management emphasized the importance of both channels, noting that while Medicaid is crucial, there is significant potential in the commercial space where only 25% of SUBLOCADE volume currently comes from [39][44] Question: Criminal justice system channel strategy - Management acknowledged the criminal justice system as an opportunity and noted stability after previous challenges, indicating a focus on growth in this area [42] Question: Future R&D spending priorities - Management plans to reorganize R&D to maintain capabilities while focusing on essential programs, with a goal to transition successful programs into Phase 3 [41] Question: Price compression on Suboxone and SUBLOCADE growth expectations - Management has not seen signs of additional price erosion for Suboxone and expects demand-driven growth for SUBLOCADE in the second half of the year [50][52] Question: Cost savings from streamlining the business - Management indicated that significant reductions in the overall cost structure are expected, with a full-year effect anticipated in 2026 [56][57] Question: Long-term market share expectations for SUBLOCADE - Management expressed confidence in SUBLOCADE's market position and noted stabilization in market share, with a focus on increasing long-acting injectable penetration [58][59] Question: Aligning SG&A spend with industry peers - Management is assessing the organization to reduce complexity and high costs, with a focus on essential spending [66][67]

Financial Data and Key Metrics Changes - Total net revenue for the second quarter was $300 million, an increase of 1% year-over-year, driven by record SUBLOCADE net revenue which offset pricing pressure on SUBOXONE Film [29][30] - Total SUBLOCADE net revenue reached $209 million, a 9% increase compared to Q2 2024, and a 19% increase sequentially, reflecting a 9% increase in dispense volume [30] - Adjusted EBITDA for the quarter was $88 million, slightly down from the previous year due to increased marketing expenses [32] Business Line Data and Key Metrics Changes - SUBLOCADE's dispense growth was 6% year-over-year and 9% sequentially, with market share in the U.S. remaining stable at approximately 75% [21] - The number of active SUBLOCADE prescribers increased by 14% year-over-year, indicating a solid base for future growth [22] - SUBOXONE Film net revenue benefited from price stability and a modestly higher market share of 14% [30] Market Data and Key Metrics Changes - The commercial channel represents a significant opportunity, with 60% of covered lives being commercial patients, yet only 25% of SUBLOCADE volume coming from this segment [47][80] - The opioid crisis continues to drive demand, with LAI penetration currently at just under 8%, indicating substantial growth potential [44][76] Company Strategy and Development Direction - The Indivior Action Agenda is a three-phased operational roadmap aimed at maximizing business potential and improving execution, with Phase One focused on generating momentum for SUBLOCADE [10][11] - The company plans to simplify operations by eliminating non-essential activities and restructuring its R&D and medical affairs organizations [12][66] - Future phases aim to accelerate profitability and cash flow generation, with a focus on commercial stage acquisitions [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed encouragement about the performance in the first half of 2025 but acknowledged the need for improvement in U.S. commercial execution [8][39] - The company raised its full-year 2025 net revenue guidance to a range of $1.03 billion to $1.08 billion, reflecting solid year-to-date performance [35] - Management emphasized the importance of operational execution to generate momentum and achieve growth targets in 2026 [17][76] Other Important Information - Indivior canceled its secondary listing on the London Stock Exchange to reduce costs and complexity [36] - The company was added to the U.S. Russell Indexes, enhancing its visibility among U.S. investors [36] Q&A Session Summary Question: Opportunity in commercially covered patients vs. Medicaid - Management acknowledged the importance of both channels, emphasizing the need to capitalize on the commercial opportunity while maintaining focus on Medicaid [40][47] Question: Criminal justice system channel strategy - Management views the criminal justice system as a growth opportunity and plans to focus on it moving forward [44] Question: R&D spending priorities - Management indicated a significant reorganization of R&D is underway, focusing on maintaining capabilities for future programs while prioritizing essential activities [43] Question: Price compression on Suboxone - Management has not seen signs of additional price erosion for Suboxone but is factoring it into guidance [50][52] Question: Cost savings from streamlining the business - Management is focused on significant reductions in the overall cost structure, with expectations for benefits to be realized in 2026 [54][56] Question: Long-term market share expectations for SUBLOCADE - Management is optimistic about SUBLOCADE's market position and believes it will stabilize in the mid-70s percentage range [58]

Q2 2025 Performance - Total net revenue increased by 1% to $302 million compared to $299 million in Q2 2024[13, 33] - SUBLOCADE net revenue grew by 9% to $209 million compared to $192 million in Q2 2024[13, 33] - Adjusted EBITDA decreased by 5% to $88 million compared to $93 million in Q2 2024[13, 33] - Gross profit increased by 14% to $250 million, with a gross margin of 83%, a 900 bps increase from 74% in Q2 2024[33] SUBLOCADE Performance - SUBLOCADE dispense growth increased by 6% year-over-year and 9% quarter-over-quarter, reaching 165,700 in Q2 2025[24] - The prescriber base for SUBLOCADE grew by 14% year-over-year, reaching 8,284 prescribers in Q2 2025[24] - The number of healthcare professionals (HCPs) with 5+ SUBLOCADE patients increased by 9% year-over-year[25] - Total SUBLOCADE patients increased by 7% year-over-year, reaching 171,519 in Q2 2025[25] Financial Guidance - The company raised its full-year 2025 total net revenue guidance to $1030 million - $1080 million from the previous guidance of $955 million - $1025 million[14, 39] - The company raised its full-year 2025 Adjusted EBITDA guidance to $275 million - $300 million, a 20% increase at the mid-points, from the previous guidance of $220 million - $260 million[39]

Core Insights - Indivior PLC reported strong financial results for Q2 2025, driven by net revenue growth from SUBLOCADE and pricing stability in SUBOXONE Film, prompting an increase in financial guidance for the year [2][4][6] Financial Performance - Total net revenue for Q2 2025 was $302 million, a 1% increase from $299 million in Q2 2024 [8][20] - SUBLOCADE net revenue reached $209 million, up 9% year-over-year and 19% compared to Q1 2025 [6][8] - U.S. SUBLOCADE net revenue was $195 million, reflecting a 9% increase from Q2 2024 and a 20% increase from Q1 2025 [7][8] - Non-GAAP gross margin for Q2 was 84%, unchanged from Q2 2024 [16] Revised Financial Guidance - The company raised its 2025 financial guidance, with total net revenue now expected to be between $1,030 million and $1,080 million, up from the previous range of $955 million to $1,025 million [4][6] - Adjusted EBITDA guidance was increased to a range of $275 million to $300 million, up from $220 million to $260 million [4][6] Strategic Initiatives - The Indivior Action Agenda is being implemented to enhance operational momentum, focusing on U.S. SUBLOCADE growth and organizational simplification [2][6] - The company has strengthened its executive team and board with new appointments to support its strategic goals [7] Market Position and Developments - Indivior has been included in the Russell 2000® Index and Russell 3000® Index, enhancing its market visibility [7] - New data presented at scientific meetings indicate that higher doses of SUBLOCADE may improve outcomes for patients with high fentanyl use [7]